Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Blesl, A; Petritsch, W; Binder, L; Fürst, S; Wenzl, H; Baumann-Durchschein, F; Kump, P; Högenauer, C.
Treatment persistence of ustekinumab and vedolizumab in IBD patients is independent of prior immunogenicity to anti-TNFs: a retrospective study.
Scand J Gastroenterol. 2022; 57(11):1327-1330
Doi: 10.1080/00365521.2022.2088248
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Blesl Andreas
- Co-Autor*innen der Med Uni Graz
- Baumann-Durchschein Franziska
- Binder Lukas
- Constantini-Kump Patrizia
- Fürst Stefan
- Hoegenauer Christoph
- Petritsch Wolfgang
- Wenzl Heimo
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND AND AIMS: Immunological treatment failure of anti-TNF therapy negatively influences treatment persistence of a second anti-TNF in IBD patients. So far it is unknown if this effect is also observed for other monoclonal antibodies. We assessed the influence of immunogenicity to anti-TNFs on treatment persistence of subsequent ustekinumab and vedolizumab therapy. METHODS: IBD patients with and without immunogenicity to anti-TNFs (undetectable trough levels and antibody titers ≥20 ng/mL) and subsequent ustekinumab (UST) and/or vedolizumab (VDZ) therapy were included in this retrospective, single-center study. The Kaplan-Meier method with the log-rank test and Cox proportional hazards were used as statistical methods. RESULTS: One hundred patients (Crohn's disease: 62, Ulcerative colitis: 31, IBD unclassified: 7) with 127 treatment lines (62 with UST, 65 with VDZ) were included in the analysis. Immunogenicity to previous anti-TNFs did not influence treatment persistence of subsequent ustekinumab and vedolizumab therapy (UST: Log rank: p = .95, Immunogenicity: HR for treatment discontinuation: 0.97 [95% CI 0.31-3.04]; VDZ: p = .65, HR: 0.85 [0.41-1.75]; total cohort [UST and VDZ]: p = .62, HR: 0.86 [0.47-1.57]). Azathioprine co-treatment did not lengthen treatment persistence (UST: Log rank: p = .77, azathioprine: HR: 1.20 [0.34-4.27]; VDZ: p = .92, HR: 0.58 [0.17-1.99]; total cohort: p = .79, HR: 1.10 [0.55-2.20]). In this anti-TNF experienced cohort, patients with ustekinumab remained longer on treatment than patients receiving vedolizumab (Log rank: p = .005, UST: HR: 0.43 [0.23-0.79]). CONCLUSIONS: Immunogenicity to anti-TNFs does not influence treatment persistence of subsequent ustekinumab and vedolizumab therapy.
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- Ustekinumab - therapeutic use
- Retrospective Studies - administration & dosage
- Tumor Necrosis Factor Inhibitors - administration & dosage
- Gastrointestinal Agents - therapeutic use
- Azathioprine - therapeutic use
- Inflammatory Bowel Diseases - drug therapy, chemically induced
- Treatment Outcome - administration & dosage
- Find related publications in this database (Keywords)
- Inflammatory bowel disease
- Crohn's disease
- ulcerative colitis
- immunogenicity
- anti-TNF
- vedolizumab
- ustekinumab